Respiratory Syncytial Virus Fusion Protein (RSV-F Protein) - Pipeline Review, H1 2016

  • ID: 3788913
  • Report
  • 121 pages
  • Global Markets Direct
1 of 6

FEATURED COMPANIES

  • Ablynx NV
  • Bavarian Nordic A/S
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences, Inc.
  • iBio, Inc.
  • mAbxience S.A.
  • MORE
Respiratory Syncytial Virus Fusion Protein (RSV-F Protein) - Pipeline Review, H1 2016

Summary

‘Respiratory Syncytial Virus Fusion Protein (RSV-F Protein) - Pipeline Review, H1 2016’, provides in depth analysis on Respiratory Syncytial Virus Fusion Protein (RSV-F Protein) targeted pipeline therapeutics.

The report provides comprehensive information on the Respiratory Syncytial Virus Fusion Protein (RSV-F Protein), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Respiratory Syncytial Virus Fusion Protein (RSV-F Protein) targeted therapeutics development and features dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Respiratory Syncytial Virus Fusion Protein (RSV-F Protein)
- The report reviews Respiratory Syncytial Virus Fusion Protein (RSV-F Protein) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Respiratory Syncytial Virus Fusion Protein (RSV-F Protein) targeted therapeutics and enlists all their major and minor projects
- The report assesses Respiratory Syncytial Virus Fusion Protein (RSV-F Protein) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Respiratory Syncytial Virus Fusion Protein (RSV-F Protein) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Respiratory Syncytial Virus Fusion Protein (RSV-F Protein)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Respiratory Syncytial Virus Fusion Protein (RSV-F Protein) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 6

FEATURED COMPANIES

  • Ablynx NV
  • Bavarian Nordic A/S
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences, Inc.
  • iBio, Inc.
  • mAbxience S.A.
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Respiratory Syncytial Virus Fusion Protein (RSV-F Protein) Overview

Therapeutics Development

Respiratory Syncytial Virus Fusion Protein (RSV-F Protein) - Products under Development by Stage of Development

Respiratory Syncytial Virus Fusion Protein (RSV-F Protein) - Products under Development by Therapy Area

Respiratory Syncytial Virus Fusion Protein (RSV-F Protein) - Products under Development by Indication

Respiratory Syncytial Virus Fusion Protein (RSV-F Protein) - Pipeline Products Glance

Late Stage Products

Early Stage Products

Respiratory Syncytial Virus Fusion Protein (RSV-F Protein) - Products under Development by Companies

Respiratory Syncytial Virus Fusion Protein (RSV-F Protein) - Products under Development by Universities/Institutes

Respiratory Syncytial Virus Fusion Protein (RSV-F Protein) - Therapeutics Assessment

Assessment by Monotherapy/Combination Products

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Respiratory Syncytial Virus Fusion Protein (RSV-F Protein) - Companies Involved in Therapeutics Development

Ablynx NV

Agilvax, Inc.

Aridis Pharmaceuticals LLC

Bavarian Nordic A/S

Celltrion, Inc.

Emergent BioSolutions Inc.

F. Hoffmann-La Roche Ltd.

Gene Techno Science Co., Ltd.

GenVec, Inc.

Gilead Sciences, Inc.

GlaxoSmithKline Plc

iBio, Inc.

Johnson & Johnson

mAbxience S.A.

MedImmune, LLC

Medivir AB

Mucosis B.V.

Navigen Pharmaceuticals, Inc.

Novavax, Inc.

Regeneron Pharmaceuticals, Inc.

Takeda Pharmaceutical Company Limited

The International Biotechnology Center (IBC) Generium

Vaxart, Inc.

VLP Biotech, Inc.

Respiratory Syncytial Virus Fusion Protein (RSV-F Protein) - Drug Profiles

(human parainfluenza virus [serotype 1] + respiratory syncytial virus) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(influenza (virus like particle) + respiratory syncytial virus) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AK-0529 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ALX-0171 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AR-201 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GNR-007 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GV-2311 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JNJ-61187165AAA - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JNJ-61187191AAA - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MEDI-7510 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MEDI-8897 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies to Inhibit RSV-G and F Proteins for RSV Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Inhibit RSV-G and RSV-F for RSV Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MVA-RSV - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

palivizumab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

palivizumab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

palivizumab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

palivizumab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

palivizumab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

presatovir - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

respiratory syncytial virus (virus like particle) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

respiratory syncytial virus (virus like particle) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

respiratory syncytial virus (virus like particle) vaccines - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

respiratory syncytial virus immune globulin (human) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

respiratory syncytial virus vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

respiratory syncytial virus vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

respiratory syncytial virus vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

respiratory syncytial virus vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

respiratory syncytial virus vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

respiratory syncytial virus vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

respiratory syncytial virus vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

respiratory syncytial virus vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

respiratory syncytial virus vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RSV-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RV-521 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Respiratory Syncytial Virus Fusion Protein for RSV Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

suptavumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SynGEM - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptides to Inhibit RSV-F Protein for RSV Infection - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Respiratory Syncytial Virus Fusion Protein (RSV-F Protein) - Dormant Projects

Respiratory Syncytial Virus Fusion Protein (RSV-F Protein) - Discontinued Products

Respiratory Syncytial Virus Fusion Protein (RSV-F Protein) - Featured News & Press Releases

Jun 02, 2016: Novavax Announces New Seasonal Combination Respiratory Vaccine Program

May 25, 2016: U.S. FDA Grants Fast Track Designation to Novavax RSV F Vaccine for Older Adults

May 23, 2016: Bavarian Nordic Announces Positive Top Line Results from a Phase 1 Trial of a Novel, Broad Spectrum RSV Vaccine in Healthy Adult and Elderly Populations

May 03, 2016: Ablynx reports positive top line results for its inhaled Anti-RSV Nanobody (ALX-0171) in a phase I/IIa Study in infants hospitalised with a RSV infection

Mar 09, 2016: First consortium of local manufacturers to make affordable biosimilars available for low income countries

Mar 04, 2016: Immune Design’s GLAAS Platform Shown to Modulate the Allergic Immune Response

Jan 20, 2016: Mucosis Secures €3.7M from Wellcome Trust to Fund Clinical Trials of its Respiratory Syncytial Virus Vaccine in Partnership with Imperial College London

Dec 21, 2015: Novavax Appoints Mark Twyman Vice President Marketing

Dec 17, 2015: Ablynx Completes Enrolment Of The First-In-Infant Phase I/IIa Safety Study With Its Anti-RSV Nanobody And Extends The Trial For Younger Infants

Dec 14, 2015: Novavax Completes Enrollment of Pivotal Phase 3 Trial of the RSV F Vaccine in Older Adults

Dec 03, 2015: Novavax Initiates Global Pivotal Phase 3 Trial of the RSV F Vaccine to Protect Infants via Maternal Immunization

Nov 19, 2015: Vaxart Presents Positive Preclinical Data for Oral RSV Vaccine at RSV Vaccines for the World Conference

Nov 16, 2015: Novavax to Make Multiple Presentations at RSV Vaccines for the World

Nov 09, 2015: Novavax Initiates Pivotal Phase 3 Trial of the RSV F Vaccine in Older Adults

Oct 29, 2015: MEDI7510 for Respiratory Syncytial Virus Advances to Phase 2 Leverages Immune Design's GLAAS Discovery Platform

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer 121List of Tables

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Indication, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Number of Products under Development by Companies, H1 2016

Number of Products under Development by Companies, H1 2016 (Contd..1)

Products under Development by Companies, H1 2016

Products under Development by Companies, H1 2016 (Contd..1)

Number of Products under Investigation by Universities/Institutes, H1 2016

Products under Investigation by Universities/Institutes, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Pipeline by Ablynx NV, H1 2016

Pipeline by Agilvax, Inc., H1 2016

Pipeline by Aridis Pharmaceuticals LLC, H1 2016

Pipeline by Bavarian Nordic A/S, H1 2016

Pipeline by Celltrion, Inc., H1 2016

Pipeline by Emergent BioSolutions Inc., H1 2016

Pipeline by F. Hoffmann-La Roche Ltd., H1 2016

Pipeline by Gene Techno Science Co., Ltd., H1 2016

Pipeline by GenVec, Inc., H1 2016

Pipeline by Gilead Sciences, Inc., H1 2016

Pipeline by GlaxoSmithKline Plc, H1 2016

Pipeline by iBio, Inc., H1 2016

Pipeline by Johnson & Johnson, H1 2016

Pipeline by mAbxience S.A., H1 2016

Pipeline by MedImmune, LLC, H1 2016

Pipeline by Medivir AB, H1 2016

Pipeline by Mucosis B.V., H1 2016

Pipeline by Navigen Pharmaceuticals, Inc., H1 2016

Pipeline by Novavax, Inc., H1 2016

Pipeline by Regeneron Pharmaceuticals, Inc., H1 2016

Pipeline by Takeda Pharmaceutical Company Limited, H1 2016

Pipeline by The International Biotechnology Center (IBC) Generium, H1 2016

Pipeline by Vaxart, Inc., H1 2016

Pipeline by VLP Biotech, Inc., H1 2016

Dormant Projects, H1 2016

Discontinued Products, H1 2016 108List of Figures

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Indication, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Stage and Mechanism of Actions, H1 2016

Number of Products by Routes of Administration, H1 2016

Number of Products by Stage and Routes of Administration, H1 2016

Number of Products by Molecule Types, H1 2016

Number of Products by Stage and Molecule Type, H1 2016
Note: Product cover images may vary from those shown
3 of 6

Loading
LOADING...

4 of 6

FEATURED COMPANIES

  • Ablynx NV
  • Bavarian Nordic A/S
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences, Inc.
  • iBio, Inc.
  • mAbxience S.A.
  • MORE
Respiratory Syncytial Virus Fusion Protein (RSV-F Protein) pipeline Target constitutes close to 38 molecules. Out of which approximately 34 molecules are developed by Companies and remaining by the Universities/Institutes. Our latest report Respiratory Syncytial Virus Fusion Protein – Pipeline Review, H1 2016, outlays comprehensive information on the Respiratory Syncytial Virus Fusion Protein (RSV-F Protein) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Respiratory Syncytial Virus Fusion Protein (RSV-F Protein) Respiratory Syncytial Virus (RSV) Fusion (F) Glycoprotein is a Class I viral fusion protein. During virus entry it induces fusion of viral and cellular membranes leading to delivery of the nucleocapsid into the cytoplasm. It interacts directly with heparan sulfate and participates in virus attachment. F2 subunit was identified as the major determinant of RSV host cell specificity. Protein F expressed at the plasma membrane of infected cells can mediate fusion with adjacent cells to form syncytia, a cytopathic effect that could lead to tissue necrosis. The fusion protein is able to trigger p53-dependent apoptosis. The molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 5, 5, 19 and 3 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 2 molecules, respectively.

Furthermore, this report also reviews key players involved in Respiratory Syncytial Virus Fusion Protein (RSV-F Protein) targeted therapeutics development, features dormant and discontinued projects and latest news and press releases. Driven by data built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Product cover images may vary from those shown
5 of 6
Ablynx NV
Agilvax, Inc.
Aridis Pharmaceuticals LLC
Bavarian Nordic A/S
Celltrion, Inc.
Emergent BioSolutions Inc.
F. Hoffmann-La Roche Ltd.
Gene Techno Science Co., Ltd.
GenVec, Inc.
Gilead Sciences, Inc.
GlaxoSmithKline Plc
iBio, Inc.
Johnson & Johnson
mAbxience S.A.
MedImmune, LLC
Medivir AB
Mucosis B.V.
Navigen Pharmaceuticals, Inc.
Novavax, Inc.
Regeneron Pharmaceuticals, Inc.
Takeda Pharmaceutical Company Limited
The International Biotechnology Center (IBC) Generium
Vaxart, Inc.
VLP Biotech, Inc.
Note: Product cover images may vary from those shown
6 of 6
Note: Product cover images may vary from those shown
Adroll
adroll